用于非小细胞肺癌异种移植模型中c-Met表达成像的SPECT示踪剂开发
研究开发了靶向c-Met的新型肽类放射性示踪剂99mTc-HYNIC-cMBP,在两种非小细胞肺癌细胞系(H1993高表达、H1299不表达)及荷瘤小鼠中进行SPECT显像评估。结果显示该示踪剂在H1993肿瘤中摄取显著高于H1299肿瘤,H1993肿瘤在注射后0.5小时即可清晰显像,而H1299肿瘤各时间点均未显像。竞争阻断实验证实了其对c-Met的结合特异性。
要点
- 99mTc-HYNIC-cMBP在H1993(高表达c-Met)细胞中摄取高于H1299(不表达)细胞。
- 注射后0.5小时H1993肿瘤摄取为4.74±1.43%/g,显著高于H1299肿瘤的1.00±0.37%/g(P<0.05)。
- SPECT显像中H1993肿瘤在0.5小时清晰可见,H1299肿瘤各时间点均未观察到。
核心结论
- 作者开发了靶向c-Met的SPECT示踪剂99mTc-HYNIC-cMBP,其可在体外和体内特异性结合c-Met并具有良好药代动力学特征,可用于非小细胞肺癌的c-Met靶向SPECT显像。
研究设计与样本
- 研究开发了新型c-Met结合肽(cMBP)放射性示踪剂99mTc-HYNIC-cMBP,在2种c-Met表达不同的非小细胞肺癌细胞系(H1993高表达、H1299不表达)中进行细胞摄取实验,并在荷瘤小鼠中于注射后0.5、1、2、4小时行SPECT显像以评估体内肿瘤特异性。
主要发现
- 99mTc-HYNIC-cMBP制备效率高,在H1993细胞中的摄取高于H1299细胞。
- 生物分布和放射自显影显示注射后0.5小时H1993肿瘤的注射剂量百分比为4.74±1.43%/g,显著高于H1299肿瘤的1.00±0.37%/g(P<0.05)。
- SPECT显像中H1993肿瘤在0.5小时清晰可见,而H1299肿瘤在任何时间点均未观察到。
- 用过量非放射性标记肽进行竞争性阻断实验证实了99mTc-HYNIC-cMBP对c-Met的特异性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elevated expression of the c-Met receptor plays a crucial role in cancers. In non-small cell lung cancer (NSCLC), aberrant activation of the c-Met signaling pathway contributes to tumorigenesis and cancer progression and may mediate acquired resistance to epidermal growth factor receptor-targeted therapy. c-Met is therefore emerging as a promising therapeutic target for NSCLC, and methods for noninvasive in vivo assessment of c-Met expression would improve NSCLC treatment and diagnosis. Methods: We developed a new c-Met-binding peptide (cMBP) radiotracer, 99mTc-hydrazine nicotinamide (HYNIC)-cMBP, for SPECT imaging. Cell uptake assays were performed on 2 NSCLC cell lines with different c-Met expressions: H1993 (high expression) and H1299 (no expression). In vivo tumor specificity was assessed by SPECT imaging in tumor-bearing mice at 0.5, 1, 2, and 4 h after injection of the probe. Blocking assays, biodistribution, and autoradiography were also conducted to determine probe specificity. Results:99mTc-HYNIC-cMBP was prepared with high efficiency and showed higher uptake in H1993 cells than in H1299 cells. Biodistribution and autoradiography also showed significantly higher percentages of the injected dose for 99mTc-HYNIC-cMBP in H1993 tumors than in H1299 tumors at 0.5 h (4.74 ± 1.43%/g and 1.00 ± 0.37%/g, respectively; P < 0.05). H1993 tumors were clearly visualized at 0.5 h in SPECT images, whereas H1299 tumors were not observed at any time. The specificity of 99mTc-HYNIC-cMBP for c-Met was demonstrated by a competitive block with an excess of nonradiolabeled peptide. Conclusion: For c-Met-targeted SPECT imaging of NSCLC, we developed 99mTc-HYNIC-cMBP, a tracer that specifically binds to c-Met with favorable pharmacokinetics in vitro and in vivo.
引用
- Han Z, Xiao Y, Wang K, et al. Development of a SPECT Tracer to Image c-Met Expression in a Xenograft Model of Non-Small Cell Lung Cancer. J Nucl Med. 2018. PMID: 29777004. doi:10.2967/jnumed.117.206730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。